Introduction {#sec1_1}
============

Thymic epithelial neoplasm is a relatively rare malignant disease arising from the thymic epithelium and comprises thymoma, thymic carcinoma, and thymic neuroendocrine carcinoma. The incidence of thymic carcinoma is much lower than that of thymoma, accounting for 1--4% of anterior mediastinal tumors, and has a high risk of invasion and metastasis \[[@B1]\]. The standard regimen of chemotherapy for thymic carcinoma has not yet been determined because of its rarity, although a combination chemotherapy that comprised (solvent-based) paclitaxel and carboplatin was recently reported to have favorable antitumor activity for advanced thymic carcinoma \[[@B2], [@B3]\]. We present the case of a previously treated thymic carcinoma where favorable antitumor effects were achieved by *nab*-paclitaxel in combination with carboplatin.

Case Presentation {#sec1_2}
=================

A 40-year-old man was admitted to our hospital in May 2013 because of progressive right-sided back pain. The patient had been surgically diagnosed with squamous cell carcinoma of the thymus in July 2009 (designated as stage II according to the Masaoka classification \[[@B4]\]) and had received postoperative thoracic irradiation. However, computed tomography (CT) scans of the chest in May 2010 showed pleural dissemination in the right thorax. The patient worked as an engineer and requested to avoid paclitaxel-induced neuropathy at that time. Therefore, he received combined chemotherapy consisting of cisplatin and docetaxel, and achieved a minor response. After the patient became refractory to this regimen, various antitumor agents, including gemcitabine, S-1, and amrubicin, were administered. However, pleural dissemination recurred and the patient\'s back pain gradually worsened, even while using opioids.

Upon admission to our hospital, CT scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax (fig. [1a](#F1){ref-type="fig"}). The serum cytokeratin 19 fragment (CYFRA) level was increased (13.9 ng/ml; normal level \<3.5 ng/ml). The patient received *nab*-paclitaxel in combination with carboplatin as described in a previous phase III trial \[[@B5]\]. He experienced grade 4 neutropenia, according to the NCI-CTCAE (National Cancer Institute -- Common Terminology Criteria for Adverse Events) version 4.0, 2 weeks after beginning chemotherapy. Therefore, the *nab*-paclitaxel administration was omitted on day 15, and the patient received granulocyte colony-stimulating factor (G-CSF) for several days. The severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. Objective tumor shrinkage was obtained after 4 cycles of chemotherapy, and the pleural effusion disappeared (fig. [1b](#F1){ref-type="fig"}). The serum CYFRA level decreased to 1.7 ng/ml, and the patient\'s back pain was relieved without any opioids.

Discussion {#sec1_3}
==========

*nab*-Paclitaxel, the 130-nm albumin-bound paclitaxel formulation, is a promising new agent for non-small cell lung cancer, breast cancer, and gastric cancer. This case report suggests that *nab*-paclitaxel, when combined with carboplatin, is also a promising therapy for thymic carcinoma. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and *nab*-paclitaxel against thymic carcinoma. Additionally, this regimen seems to be active against previously treated or refractory thymic carcinoma. In a published series, a combination chemotherapy that comprised (solvent-based) paclitaxel and carboplatin was reported to have favorable antitumor activity and a response rate in approximately one-third of patients with thymic carcinoma \[[@B2]\]. Considering its efficacy against thymic carcinoma, *nab*-paclitaxel in combination with carboplatin could possibly be expected to achieve tumor regression in this case.

In a preclinical study, intratumoral accumulation of *nab*-paclitaxel was reported to be 33% higher than that of solvent-based paclitaxel, indicating that *nab*-paclitaxel accumulated more effectively within tumors \[[@B6]\]. Recently, weekly *nab*-paclitaxel plus carboplatin resulted in a significantly improved overall response rate, compared with that of solvent-based paclitaxel plus carboplatin, in non-small cell lung cancer treatment \[[@B5]\]. In particular, patients with squamous cell histology responded remarkably well to treatment with *nab*-paclitaxel, with a 68% improvement rate over that in the solvent-based paclitaxel arm, suggesting that *nab*-paclitaxel is a favorable agent for a squamous subset. The most common histologic type of thymic carcinoma in Japan is squamous cell carcinoma \[[@B7]\]. Therefore, *nab*-paclitaxel in combination with carboplatin is considered an optional regimen for thymic carcinoma.

Conclusion {#sec1_4}
==========

According to our experience, a case of advanced thymic carcinoma responded to treatment with *nab*-paclitaxel and carboplatin, which can be a useful chemotherapy regimen for thymic carcinoma.
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